System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gabriele Capurso is an expert in Gastroenterology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Gabriele Capurso in the top 1% of experts worldwide for Pancreatic Diseases, Pancreatic Neoplasms and Pancreatitis. Gabriele Capurso has authored 735 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 12 of them ongoing. SLR score: 2,629 (community average: 125). How the SLR is computed.

LeadR Profile

Gabriele Capurso IRCCS Ospedale San Raffaele Italy
2 629 ScienceLeadR Reputation 2629

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Medical Imaging - Oncology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

IRCCS Ospedale San Raffaele

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 735

Citations

Citations: 13 962 1st author: 83 Last author: 153 Unique author: 2

Main journals

Dig Liver Dis 167
Pancreatology 138
Gastroenterology 46
Endoscopy 39
United European Gastroenterol J 34

Best Journals

J Clin Oncol 2
Lancet Gastroenterol Hepatol 2
Ann Intern Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Aetiology-Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO-PEI Registry.
PMID 42827323 — registries, pancreatic neoplasms, pancreatitis, chronic, neoplasms, signs and symptoms, pancreatitis, enzymes, therapeutics, gastrointestinal diseases, pancreatectomy		United European Gastroenterol J20260
Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma.
PMID 42743889 — treatment outcome, neoplasms, adenocarcinoma, neoadjuvant therapy, drug tapering, therapeutics		Eur J Cancer20260
Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer.
PMID 42776526 — genes, pancreatic neoplasms, incidence, neoplasms, cohort studies, cysts, pancreatic ducts		JAMA Netw Open20260
The future of integrated treatment for PDAC: Learning from the past, advancing for the better.
PMID 42744674 — therapeutics, learning		Dig Liver Dis20260
Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma.
PMID 42717278 — pancreatic neoplasms, adenocarcinoma, neoadjuvant therapy, diagnosis, therapeutics, general surgery		Ann Surg20260

Clinical Studies 21

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 17
Phase 2 2
Phase 4 2

By status:

Recruiting 13
Completed 4
Not yet recruiting 2
Unknown 2

By type:

Observational 14
Interventional 7

By Monocentric/Multicentric:

monocentric 13
multicentric2to4 2
multicentric5to9 2
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Pancreatic Cancer Lifestyle Evolution And Resistance
NCT07794969 — pancreatic neoplasms, life style, microplastics, environmental pollutants, neoplasms, rna-seq, drug therapy, solutions, therapeutics, smoking, needles, chemotherapy		N/ANot yet recruiting2026
A study to evaluate safety and explore efficacy of new lipase NHS7108 compared with pancrelipase in adult participants with exocrine pancreatic insufficiency
2025-521816-20-00 — exocrine pancreatic insufficiency, lipase, safety, cross-over studies, pancrelipase		Phase 2Not yet recruiting2026
Open label randomized multicentre controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer
2023-507367-18-00 — pancreatic neoplasms, neoplasms, enzymes, enzyme replacement therapy, therapeutics		Phase 4Recruiting2024
Panuri Performance Study
NCT07587866 — pancreatic neoplasms, neoplasms, adenocarcinoma		N/ARecruiting2026
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency
NCT07559175 — escherichia, exocrine pancreatic insufficiency, lipase, safety, fibrosis, pharmaceutical preparations, amylases, cross-over studies, pancrelipase, bacillus, diet, capsules, cystic fibrosis, enzymes, escherichia coli, peptide hydrolases, therapeutics, meals, bacteria, triglycerides, snacks, absorption, pancreatic diseases		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS